While lixisenatide was found to be the only GLP-1RA subtype to increase the risk of MI, it is important to consider that the ELIXA trial, which studied lixisenatide in patients with T2DM, had the highest risk population as it included participants with recent acute coronary events in the past 180 days [40]
Purity-tested per lot
This is an off-label use (when a patient uses a drug that is approved to treat a condition different than your condition, according to the Agency for Healthcare Research and Quality), so the outcomes do not have the same rigorous testing as used in children and adolescents
It's not seen with: Semaglutide (Wegovy/Ozempic): 10% body weight quickly Hypoglycemia (Low Blood Sugar): Rare in non-diabetics ( perceived benefit) Timeline of Side Effects: What to Expect Week by Week Week 14: Initial Dose (2mg) What's happening: Body adjusting to GLP-1 activation Common side effects: Mild nausea (2030%): Usually 12 hours after injection Reduced appetite (desired!) Occasional loose stools Mild fatigue Duration: Usually 25 days after each injection, then improves Management: Take with food, stay hydrated, avoid high-fat meals Week 58: First Dose Increase (4mg) What's happening: GLP-1 effects intensifying Common side effects: Nausea increases (3040%) Diarrhea or constipation (1525%) Fullness sensation (desired effect) Energy fluctuations Duration: Peak in first 23 days after dose increase, then stabilizes Management: Smaller, more frequent meals
To know more, keep reading and book us
This represents a meaningful quality-of-life improvement even though the underlying structural issue persists
